Glucose Health, Inc. USPTO Patent Filing Confirms First Use of GLUCODOWN® Underlying Nutritional Composition


BENTONVILLE, AR, December 28, 2021 (GLOBE NEWSWIRE) – Glucose Health, Inc. (OTC Pink: GLUC) (“Company”) is pleased to announce that a patent application for “Compositions and Methods for Metabolic Health” has been filed with the United States Trademark and Patent Office (USPTO) on December 23, 2021, at Company Name.

The patent application discloses a composition of the combination of resistant dextrin, corosolic acid and chromium picolinate, in measures to maintain and improve health by mitigating post-meal blood sugar and lipid increases and / or lowering levels. glucose and plasma lipids. The disclosed composition is the nutritional basis of the Company’s GLUCODOWN® products.

The purpose of the USPTO filing is to assert the claims and rights of Glucose Health, Inc. as to how the composition may be used. Prior to filing, a worldwide patent search was ordered which indicated that the composition disclosed by the Company is its first use, in the context of a nutritional product, in the world.

About Glucose Health, Inc. (OTC Pink: GLUC)

By focusing on creating delicious, nutritionally appropriate beverages1 for the country’s 100+ million2 pre-diabetic and type 2 diabetics, Glucose Health, Inc., the maker of GLUCODOWN®, occupies a unique position among emerging beverage companies. . Launched in the third quarter of 2018, the Company’s GLUCODOWN® is the leading brand in the market for new and innovative, diabetic-friendly and delicious drinks. Glucose Health, Inc. is a publicly traded company with the OTC Pink ticker symbol: GLUC.

To purchase GLUCODOWN®, visit our Amazon store at: www.amazon.com/glucodown

Like us on Facebook at: www.facebook.com/glucodown

For more information on GLUC, visit: www.glucosehealthinc.com

1 For quotes, visit www.glucodown.com/data-cliniques

2 Review of National Diabetes Statistics, 2020; Centers for Disease Control and Prevention, Department of Health and Human Services

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and although Glucose Health, Inc. is not subject to the Securities and Exchange Act of 1934, contains statements forward-looking within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical fact constitute forward-looking statements and can often, but not always, be identified by the use of words such as “expects”, “anticipates”, “intention”, ” estimates “,” plans, “” potential “,” possible “,” probable “,” believes “,” research “,” may “,” could “,” should “,” could “or the negative of these terms or other similar expressions. Actual results may differ materially from those presented in this press release due to the risks and uncertainties inherent in the Company’s activities. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the company assumes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Contact:

Murray fleming

Glucose Health, Inc.

[email protected]

(479) 802-3827


Comments are closed.